BCAB Company Profile and Key Details

BioAtla, Inc. generated EPS of -$1.15 over the past year. Five-year average earnings growth is -10.97%. The latest quarter delivered EPS of -$8.00. The next quarter is forecast at $nan. Next year's EPS is expected at $7.81. BioAtla, Inc. earnings surprise history is a mixed track record. The quarter that ended March 31, 2026, missed forecasts by -33.33%. The prior quarter beat by -12.9%. Over the last six quarters, Apple has recorded several small beats. These include -35.29% in November 07, 2024.

BCAB has shown mixed momentum, gaining 1.87% over the past week and -61.36% over the past quarter, though year-to-date performance is down -43.53%. Short-term trend indicators are bullishly aligned (SMA20 23.42%, SMA50 -38.38%, SMA200 -54.52%). The stock’s 14-day RSI is 47.87 (neutral), while the ATR of 0.04 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -83.4% below its high and over 82.62% above its low. Average 10-day trading volume of 27.54 thousand shares is below the 3-month average of 39.34 thousand, indicating normal recent market interest.

BioAtla, Inc. (NASDAQ:BCAB) closed at $4.37 USD, losing -$0.03 (-0.68%) from the previous close of $4.40. The stock is currently mid-range between its 52-week high and low $3.92 and $71.50. With a market capitalization of about $5.14 million, BioAtla, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.79). Key stats such as the average daily volume over the past year has been around 38.98 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, BioAtla, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jay Short, the company employs approximately 61 people and listed since December 16, 2020. BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

BioAtla, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.58. This means the shares are trading below this model’s fair value.

BioAtla, Inc. has 82.85 million shares outstanding. The public float is 49.07 million shares, elevated short interest at 2.48% of float. This equals 1.92 million shares. The short ratio is 1.12 days. Institutional investors hold 33.28% of the float. Insiders own 10.58%. SHORT JAY M PHD holds 1.44 million shares, Smith Scott Andrew has 345.66 thousand shares and Levy Guy has 217.36 thousand shares.

BioAtla, Inc. (NASDAQ:BCAB) shares are down -43.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BioAtla, Inc. trading at a premium to the broader market with a P/E of -0.09. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $26.81, suggesting 513.5% upside. Our AI forecast model points to short-term weakness (-25.86% over two weeks), a medium-term fall (-91.53% over three months), and a longer-term loss (-75.74% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that BioAtla, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.86%, with price expected at $3.24 by May 28, 2026, within a range of $2.18 to $4.29 3-Month Outlook: Projected fall of -91.53%, reaching $0.37 by August 12, 2026, with a range of $0.00 to $2.14. 1-Year Outlook: Projected loss of -75.74%, with price at $1.06 by May 14, 2027, within a range of $0.00 to $0.00.

BioAtla, Inc. trades at a P/E ratio of -0.09, slightly below the S&P 500 average, with a price-to-sales ratio of 2.61 and a price-to-book ratio of -0.14 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.15, also above market averages.